Revance Releases Second Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Revance Therapeutics (RVNC) Reports In-Line Q2 EPS
August 2, 2018 5:08 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.94), in-line with the analyst estimate of ($0.94). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $510 thousand.
GUIDANCE:
Revance reiterates its financial guidance provided in January 2018.... More
